Multiple Myeloma

Discover our initiatives in various therapeutic areas

Carfilzomib SPC

Carfilzomib SPC® is indicated for the treatment of Multiple myeloma (MM).

Strength:

60 mg

Dosage Form:

Vial for injection.

Active ingredient:

Carfilzomib

Bortezomib SPC

Bortezomib SPC® is indicated for the treatment of:

Multiple myeloma (MM).

Mantle cell lymphoma (MCL).

Strength:

3.5 mg

Dosage Form:

Vial for injection.

Active ingredient:

Bortezomib

Pomalidomide SPC

Pomalidomide SPC® is indicated for the treatment of Multiple myeloma (MM).

Strength:

1 mg 2 mg 3 mg 4 mg

Dosage Form:

Capsule

Active ingredient:

Pomalidomide

Lenalidomide SPC

Lenalidomide SPC® is indicated for the treatment of:

Multiple myeloma (MM).

Myelodysplastic syndrome (MDS).

Mantle cell lymphoma (MCL).

Strength:

5 mg 10 mg 15 mg 20 mg 25 mg

Dosage Form:

Capsule

Active ingredient:

Lenalidomide